Why Choose Synthesis For Your Psilocybin Experience?
The beautiful and supportive setting we offer not only speaks for itself, but is also scientifically endorsed. Recent research by the Psychedelic Research Group at Imperial College, London has demonstrated that the benefits of using psychedelic medicine in a structured, group, ceremonial context, such as we create at our retreats, are greater than the benefits of taking psychedelics in an informal, unstructured setting. Synthesis participants contributed data to this study, and we have been working with Imperial to measure the positive impact of our retreats since our pilot in April 2018.
Furthermore, we pay close attention to the clinical conditions in which the team at Imperial conduct their research with psilocybin, so that we can offer equivalent transformational possibilities to our guests. Correspondingly, the findings of Imperial on data collected from Synthesis participants reflect the positive discoveries on the therapeutic potential psilocybin in clinical research, including data on improvements to mental wellbeing, the ability to have mystical experiences, lasting personality changes, and reduced depression and anxiety.
Read more about our participation in the Imperial College London Ceremony Study »
A word of caution: Synthesis does not claim to treat depression
The phenomenon that psilocybin can function as a psychotherapeutic agent that could treat depression has recently become of its most widely-reported medicinal properties.
Increasing numbers of studies from psychedelic research teams at top academic institutions worldwide have been researching psilocybin, the active component of magic mushrooms, as a remedy for treatment-resistant depression. They have, collectively, built a strong evidence base for its efficacy that the Food and Drug Administration (FDA) has granted psilocybin-assisted therapy a Breakthrough Therapy designation. This means that, rather than blocking the progress of further investigations, the FDA are likely to greenlight its development into an available treatment option, should the clinical trials that are currently underway in Europe and North America prove successful.
Synthesis gives participants who opt in to the study the same questionnaire which the team at Imperial uses to document the lasting reductions in depressive symptoms which psilocybin-assisted therapy can bring about in clinical studies. It is important to note that everybody is affected by depression, to some degree. Everybody who takes the test will get a depression score, regardless of whether they have (or would be given) a clinical diagnosis of depression or not. Possible results for this test range from the lowest scoring category of no depression, through to mild, moderate, severe, and finally, very severe depression.
Unfortunately at this point in time, we can not accept anyone with a clinical diagnosis of depression, and, correspondingly, our participants’ baseline depression scores are usually low. Nevertheless, echoing the findings on the lasting positive effects of psilocybin from the Imperial team, the guests at Synthesis experienced a sustained reduction in depressive symptoms. At the two- and four-week follow-ups after their psilocybin ceremony, their scores remained significantly lowered, compared to their scores before attending the retreat.
Synthesis does not claim to treat depression. The fact that, in our data, our participants exhibit enduringly reduced scores in follow-up questionnaires, is a potential testament to the positive impact on a person’s overall wellbeing that attending a psilocybin ceremony at Synthesis can have. However, these results should not be interpreted as a suggestion that attending a Synthesis retreat can serve as a treatment for depression.
If you are keen to experience psychotherapy with psilocybin as a treatment for depression in a safe, legal setting, you can apply to take part in a clinical trial.